Clinical Trials

Numerous clinical trials evaluate levetiracetam across neurological indications, primarily targeting epilepsy, status epilepticus, febrile convulsions, partial-onset seizures, glioma-associated seizures, and maternal drug transfer during pregnancy. Spanning Phase 1 through Phase 4 alongside observational studies, these protocols are supported by pharmaceutical and academic sponsors. Current recruitment statuses across the portfolio range from completed and actively recruiting to terminated studies and those not yet recruiting.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07220902 NOT_YET_RECRUITING
Severe Preeclampsia; Eclampsia Preeclampsia
Nebraska Methodist Health System
 2026-01-01 PHASE3
NCT06442748 RECRUITING
Seizures; Brain Tumors; Antiepileptics; Levetiracetam
Tata Memorial Centre
 2024-07-04 PHASE3
NCT07336992 NOT_YET_RECRUITING
Spontaneous Intracerebral Hemorrhage
Hospices Civils de Lyon
 2026-10-02 PHASE3
NCT07758062 NOT_YET_RECRUITING
Glioblastoma
Tianjin Medical University General Hospital
 2026-09-01 PHASE2
NCT06907173 RECRUITING
Status Epilepticus
University of Virginia
 2026-03-06 PHASE3
NCT07130786 RECRUITING
Seizures; Primary Motor Cortex; Brain Metastases From Non-small Cell Lung Cancer (NSCLC); Brain Metastases, Adult; Brain Metastases From Extra-cranial Solid Tumors
Ayal A. Aizer, MD
 2025-12-23 PHASE2
NCT06773364 RECRUITING
Suspected Stroke
Shanghai East Hospital
 2025-04-30 PHASE3
NCT07490769 RECRUITING
Epilepsy
Waad Alkathiri
 2025-10-01 PHASE3
NCT03048084 RECRUITING
Glioma
Leiden University Medical Center
 2018-02-01 PHASE4
NCT07477431 RECRUITING
Hippocampal Hyperactivation; Prodromal Alzheimer Disease
Sunnybrook Health Sciences Centre
 2025-10-23 PHASE2
NCT07234695 RECRUITING
Down Syndrome; Down Syndrome (DS); Down Syndrome (Trisomy 21); Alzheimer Dementia; Alzheimer Dementia (AD); Alzheimer Disease; Alzheimer Disease (AD); Alzheimer Blood Biomarkers; Epilepsy; Seizures
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
 2025-12-22 PHASE3
NCT05735717 RECRUITING
Hematologic Malignancy; Acute Leukemia; Remission; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; AML; TP53; Intrachromosomal Amplification of Chromosome 21; Cytogenetic Abnormality; CNS Leukemia; Minimal Residual Disease; Myelodysplasia; Juvenile Myelomonocytic Leukemia; Somatic Mutation; PTPN11 Gene Mutation; N-RAS Gene Amplification; Neurofibromatosis 1; NF1 Mutation; CBL Gene Mutation; Monosomy 7; Chromosome Abnormality; Fetal Hemoglobin; Lymphoblastic Lymphoma; High Grade Non-Hodgkin's Lymphoma, Adult
Masonic Cancer Center, University of Minnesota
 2023-05-11 PHASE2
NCT05610085 RECRUITING
Neonatal Seizure; Neonatal Encephalopathy; Hypoxic-Ischemic Encephalopathy; Seizure Newborn
University of California, San Diego
 2023-03-24 PHASE2
NCT06851078 NOT_YET_RECRUITING
Septic Shock
Assistance Publique - Hôpitaux de Paris
 2025-03-15 PHASE3
NCT07271966 RECRUITING
Brain Tumor Related Epilepsy (BTRE)
Duke University
 2026-05-29
NCT06919926 ACTIVE_NOT_RECRUITING
Hippocampal Overactivity; Dementia
Johns Hopkins University
 2025-04-17 PHASE2
NCT06866691 RECRUITING
Traumatic Brain Injury
Wake Forest University Health Sciences
 2025-04-18 PHASE4
NCT07072624 RECRUITING
Seizures; Traumatic Brain Injuries; Traumatic Brain Injury (TBI) Patients
All India Institute of Medical Sciences, Jodhpur
 2025-07-23 PHASE4
NCT06345495 RECRUITING
Splenomegaly; Myelofibrosis
M.D. Anderson Cancer Center
 2024-10-01 PHASE2
NCT07239115 RECRUITING
Postoperative Seizures After Brain Tumor Surgery
Beijing Tiantan Hospital
 2026-05-14 PHASE3
NCT07284498 NOT_YET_RECRUITING
Neonatal Seizures; HIE - Hypoxic - Ischemic Encephalopathy
Mansoura University
 2026-01-01 PHASE4
NCT04833907 ENROLLING_BY_INVITATION
Canavan Disease
Myrtelle Inc.
 2021-04-01 PHASE1; PHASE2
NCT06224530 RECRUITING
Psychosis
King's College London
 2024-07-19
NCT07046611 RECRUITING
Generalized Convulsive Status Epilepticus
Sohag University
 2025-07-02 PHASE2; PHASE3
NCT07098728 RECRUITING
Seizure
Ministry of Health and Sports, Myanmar
 2025-07-22
NCT04573803 NOT_YET_RECRUITING
Traumatic Brain Injury; Post Traumatic Seizures
Cambridge University Hospitals NHS Foundation Trust
 2021-03-01 PHASE3
NCT05897658 NOT_YET_RECRUITING
Seizures; Brain Tumor
Hamilton Health Sciences Corporation
 2025-03 PHASE3
NCT03875638 COMPLETED
Alzheimer Dementia; Alzheimer Disease; Dementia of Alzheimer Type; Mild Cognitive Impairment
Beth Israel Deaconess Medical Center
 2019-08-22 PHASE2
NCT07393022 COMPLETED
Pharmacokinetic Analysis; Bioequivalence; Health Adult Subjects
Desitin Arzneimittel GmbH
 2025-12-17 PHASE1
NCT07422233 COMPLETED
Epilepsy; Elderly
Nasim Tabrizi
 2023-09-13 PHASE4
NCT05969054 UNKNOWN
Alzheimer Disease 3; Epilepsy
Xiangya Hospital of Central South University
 2023-07-05 PHASE4
NCT07163572 COMPLETED
Status Epilepticus
Muhammad Aamir Latif
 2025-01-16
NCT07163585 COMPLETED
Epilepsy
RESnTEC, Institute of Research
 2024-08-01
NCT07052136 COMPLETED
Status Epilepticus
RESnTEC, Institute of Research
 2024-11-01
NCT04317807 COMPLETED
Early Psychosis
NYU Langone Health
 2020-08-27 PHASE2
NCT07401433 COMPLETED
Neonatal Seizures
Hayat Abad Medical Complex, Peshawar
 2024-04-08
NCT04643327 RECRUITING
Parkinson Disease; Mild Cognitive Impairment; Memory Impairment
The University of Queensland
 2021-02-09 PHASE2
NCT06081283 TERMINATED
Brain Injuries, Acute; Brain Injuries, Traumatic; Brain Ischemia; Brain Hypoxia; Hypoxia-Ischemia, Brain; Heart Arrest; Stroke; Intracranial Hemorrhages; Coma; Persistent Vegetative State
University of North Carolina, Chapel Hill
 2023-11-20 PHASE4
NCT04004702 UNKNOWN
Alzheimer Disease
Walter Reed National Military Medical Center
 2020-01 PHASE2
NCT02647437 COMPLETED
Schizophrenia
University of Colorado, Denver
 2013-06
NCT04759196 UNKNOWN
Chronic Subdural Hematoma; Epilepsy; Seizure; Cortical Depression; Cortical Depolarization; Nonepileptic, Stereotypical and Intermittent Symptoms; NESIS
Université de Sherbrooke
 2021-03-01 PHASE4
NCT06403150 UNKNOWN
Status Epilepticus
Dhaka Medical College
 2023-05-15 PHASE4
NCT03689114 COMPLETED
Epilepsies, Partial
Mario Negri Institute for Pharmacological Research
 2021-05-10 PHASE4
NCT03034356 COMPLETED
Schizophrenia
VA Office of Research and Development
 2018-08-15 PHASE1; PHASE2
NCT05722951 COMPLETED
Epilepsy
Tanta University
 2022-10-18 PHASE3
NCT04836559 COMPLETED
Focal Onset Seizures
Janssen Research & Development, LLC
 2021-05-18 PHASE2
NCT05860153 UNKNOWN
Febrile Convulsion
Assiut University
 2023-06-01
NCT04559529 COMPLETED
Schizophrenia; Psychosis
Vanderbilt University Medical Center
 2020-09-23 PHASE2
NCT01801072 COMPLETED
Intracranial Aneurysms; Seizure
University of Michigan
 2013-02 PHASE4
NCT04117425 COMPLETED
Epilepsy in Pregnancy
Assistance Publique - Hôpitaux de Paris
 2022-04-20
NCT04858841 UNKNOWN
Middle Cerebral Artery Stroke
National Cheng Kung University
 2020-08-01
NCT02348216 COMPLETED
Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma (TFL); Primary Mediastinal B-cell Lymphoma (PMBCL); High Grade B-cell Lymphoma (HGBCL)
Kite, A Gilead Company
 2015-04-21 PHASE1; PHASE2
NCT04939675 UNKNOWN
Epilepsy
National Taiwan University Hospital
 2021-07-01
NCT05860153 Not yet recruiting
Febrile Convulsion
Assiut University
 2023-06-01 Not Applicable
NCT06403150 Enrolling by invitation
Status Epilepticus
Dhaka Medical College
 2023-05-15 Phase 4
NCT06067412 COMPLETED
Status Epilepticus
Shaheed Zulfiqar Ali Bhutto Medical University
 2022-08-01
NCT04926844 COMPLETED
Status Epilepticus; Generalized Convulsive Status Epilepticus; Status Epilepticus, Generalized; Status Epilepticus, Generalized Convulsive
Sohag University
 2021-06-20 PHASE2
NCT06067412 Completed
Status Epilepticus
Shaheed Zulfiqar Ali Bhutto Medical University
 2022-08-01 Not Applicable
NCT04425798 Unknown status
Glioma|Epilepsy
Beijing Neurosurgical Institute|Beijing Tiantan Hospital
 2022-05-25 --
NCT04117425 Recruiting
Epilepsy in Pregnancy
Assistance Publique - Hôpitaux de Paris
 2022-04-20 Not Applicable
NCT03489044 COMPLETED
Alzheimer Disease; Epilepsy
University of Oxford
 2018-10-28 PHASE2
NCT02229123 COMPLETED
Neonatal Seizures
University Hospital, Tours
 2018-02-27 PHASE2
NCT00227461 UNKNOWN
Aphasia; Stroke
Kessler Foundation
 2005-09 PHASE1
NCT03129360 COMPLETED
Psychosis; Schizophrenia; Schizo Affective Disorder; Schizophreniform
NYU Langone Health
 2017-08-18 PHASE2
NCT01857934 COMPLETED
Neuroblastoma
St. Jude Children's Research Hospital
 2013-07-05 PHASE2
NCT05008354 COMPLETED
Epilepsy; Pyridoxine; Behavior Problem
Nasim Tabrizi
 2020-10-01 PHASE4
NCT03340064 COMPLETED
Partial Seizures
UCB Japan Co. Ltd.
 2017-11-30 PHASE3
NCT04172311 UNKNOWN
Refractory Childhood Epilepsy
Lady Hardinge Medical College
 2019-11-14 PHASE2; PHASE3
NCT03436433 TERMINATED
Glioma; Glioma of Brain; Brain Tumor
Duke University
 2019-01-31 PHASE2
NCT02334722 COMPLETED
Brain Neoplasms; Brain Cancer; Brain Tumors; Cancer of the Brain; Cancer of Brain; Seizure
University of Florida
 2015-08-05 PHASE4
NCT04610879 TERMINATED
Rolandic Epilepsy
King's College London
 2019-08-02 PHASE4
NCT04277936 TERMINATED
Schizophrenia; Psychosis
Vanderbilt University Medical Center
 2020-05-11 PHASE2
NCT02002819 COMPLETED
Alzheimer's Disease
University of Minnesota
 2014-10-16 PHASE2
NCT02201251 COMPLETED
Epilepsy
Janssen Research & Development, LLC
 2014-10-06 PHASE3
NCT03054285 UNKNOWN
Seizures; Traumatic Brain Injury
Loyola University
 2017-07-01 PHASE4
NCT04176887 UNKNOWN
Comparison; the Efficacy of Levetireacetam; Phenytoin; Management of Pediatric Status Epilepticus
Tanta University
 2019-01-01 PHASE4
NCT03940326 COMPLETED
Epilepsy, Idiopathic Generalized
Mazandaran University of Medical Sciences
 2018-04-01 PHASE4
NCT03116828 COMPLETED
Epilepsy With Partial On-set Seizures
Sumitomo Pharma America, Inc.
 2017-07-07 PHASE4
NCT02815410 UNKNOWN
Glioblastoma Multiforme
Seoul National University Hospital
 2016-07 PHASE2
NCT03695094 COMPLETED
Epilepsy
UCB Biopharma S.P.R.L.
 2018-09-18 PHASE1
NCT01960075 COMPLETED
Benzodiazepine Refractory Status Epilepticus
University of Virginia
 2015-10 PHASE3
NCT00489281 TERMINATED
Sickle Cell Disease
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 2008-06-23 PHASE2
NCT02707965 COMPLETED
Epilepsy
Food and Drug Administration (FDA)
 2017-06-08 PHASE1
NCT01720667 COMPLETED
Neonatal Seizures
Richard H. Haas
 2013-03 PHASE1; PHASE2
NCT03107507 UNKNOWN
Neonatal Seizures
Cairo University
 2017-03-25 PHASE4
NCT02602860 COMPLETED
Healthy Volunteers
UCB Pharma
 2015-11 PHASE1
NCT01554683 COMPLETED
Alzheimer's Disease; Seizures
Beth Israel Deaconess Medical Center
 2012-02
NCT01521130 COMPLETED
Benign Childhood Epilepsy With Centro-Temporal Spikes
Children's Hospital Medical Center, Cincinnati
 2012-01 PHASE1
NCT02374567 TERMINATED
Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
Hannover Medical School
 2015-01 PHASE3
NCT02550028 TERMINATED
Neonatal Seizures
Children's Hospital of Fudan University
 2015-09-01 PHASE1; PHASE2
NCT02726867 WITHDRAWN
Epilepsy; Status Epilepticus
Mid-Atlantic Epilepsy and Sleep Center, LLC
 2014-02 PHASE3
NCT02920060 COMPLETED
Grand Mal Status Epilepticus
Banaras Hindu University
 2015-01 PHASE2
NCT01398956 COMPLETED
Epilepsy; Generalized Tonic-clonic Seizures
UCB Pharma
 2011-06 PHASE3
NCT02199509 COMPLETED
Oromandibular Dystonia; Cranial Dystonia
National Institute of Neurological Disorders and Stroke (NINDS)
 2014-07 PHASE2
NCT01974700 TERMINATED
Intracranial Aneurysms; Seizures
Indiana University
 2013-07 PHASE4
NCT01891890 TERMINATED
Epilepsy, Partial; Epilepsy, Localization Related
Emory University
 2013-08 PHASE3
NCT01954121 COMPLETED
Epilepsy; Partial Seizures
UCB Pharma SA
 2013-09 PHASE3
NCT01392768 COMPLETED
Epilepsy; Partial Seizures
Ache Laboratorios Farmaceuticos S.A.
 2013-01 PHASE3
NCT01982812 COMPLETED
Seizure; Epilepsy; Cerebral Malaria
University of Rochester
 2014-01 PHASE2
NCT01229735 COMPLETED
Epilepsy
UCB Korea Co., Ltd.
 2010-11 PHASE4
NCT01498822 COMPLETED
Epilepsy
Korea UCB Co., Ltd.
 2011-06 PHASE4
NCT01228747 COMPLETED
Epilepsy; Generalized Tonic-Clonic Seizures
UCB Japan Co. Ltd.
 2010-10 PHASE3
NCT01345058 COMPLETED
Epilepsy
Brigham and Women's Hospital
 2011-08-01 PHASE3
NCT01484977 COMPLETED
Epilepsy
UCB Pharma
 2011-12 PHASE3
NCT02208492 COMPLETED
Focal Epilepsy
Yonsei University
 2011-09 PHASE4
NCT01653262 COMPLETED
Epilepsy
UCB Pharma SA
 2012-07 PHASE3
NCT01464359 TERMINATED
Acute Myelogenous Leukemia; Refractory Acute Myelogenous Leukemia
Masonic Cancer Center, University of Minnesota
 2011-10 PHASE2
NCT01506882 COMPLETED
Epilepsy; Partial Onset Seizures
UCB Japan Co. Ltd.
 2011-12 PHASE3
NCT00862563 TERMINATED
Alcoholism; Alcohol Dependence; Alcohol Abuse
Boston Medical Center
 2009-05 PHASE2
NCT01660672 COMPLETED
Seizure; Epilepsy; Cerebral Malaria
University of Rochester
 2013-01 PHASE1; PHASE2
NCT01292837 COMPLETED
Epilepsy; Generalized Tonic-clonic Seizures
UCB Japan Co. Ltd.
 2011-02 PHASE3
NCT01935908 WITHDRAWN
Subarachnoid Hemorrhage; Seizures
Vanderbilt University Medical Center
 2013-05 PHASE4
NCT01150331 COMPLETED
Status; Epilepticus, Tonic-clonic
Assistance Publique - Hôpitaux de Paris
 2009-07 PHASE3
NCT01375374 TERMINATED
Epilepsy, Partial
UCB Pharma
 2011-07 PHASE3
NCT01137110 COMPLETED
Subarachnoid Hemorrhage
Washington University School of Medicine
 2010-05-01
NCT01725009 COMPLETED
Healthy Volunteers
UCB Japan Co. Ltd.
 2012-10 PHASE1
NCT01491113 COMPLETED
Healthy Subjects; Renal Impairments
UCB Pharma
 2011-11 PHASE4
NCT00916149 COMPLETED
Epilepsy
Massachusetts General Hospital
 2007-01
NCT01618903 COMPLETED
Human Volunteers
UCB Pharma
 2012-05 PHASE1
NCT01044758 COMPLETED
Mild Cognitive Impairment (MCI)
Johns Hopkins University
 2009-12 PHASE2
NCT01618877 COMPLETED
Human Volunteers
UCB Pharma
 2012-05 PHASE1
NCT00774306 TERMINATED
Subarachnoid Hemorrhage
Thomas Jefferson University
 2009-04
NCT00537238 COMPLETED
Partial Seizures
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2007-10 PHASE3
NCT00629889 COMPLETED
Brain and Central Nervous System Tumors; Seizure
Dr Andrea Rossetti
 2008-02 PHASE2
NCT01407523 COMPLETED
Epilepsy; Partial Onset Seizures
UCB Japan Co. Ltd.
 2011-07 PHASE2
NCT01394224 COMPLETED
Healthy Volunteers
UCB Pharma
 2011-06 PHASE1
NCT01239212 COMPLETED
Seizures
Children's Hospital Medical Center, Cincinnati
 2010-09 PHASE1; PHASE2
NCT00894010 COMPLETED
Photosensitive Epilepsy
The Epilepsy Study Consortium
 2009-05 PHASE2
NCT01063764 COMPLETED
Epilepsy; Partial Seizures
UCB Japan Co. Ltd.
 2010-01 PHASE3
NCT00884052 COMPLETED
Seizures; Disorder of Fetus or Newborn
Richard H. Haas
 2007-04 PHASE1; PHASE2
NCT00367432 COMPLETED
Epilepsies; Partial
UCB Japan Co. Ltd.
 2006-07 PHASE3
NCT00970814 COMPLETED
Alcoholism
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
 2009-10 PHASE2
NCT00438451 COMPLETED
Focal Epilepsy
Johannes Gutenberg University Mainz
 2007-01 PHASE4
NCT00465244 WITHDRAWN
Seizures
Massachusetts General Hospital
 2008-01 PHASE2; PHASE3
NCT00563459 TERMINATED
Epilepsy; Seizures
SK Life Science, Inc.
 2007-11 PHASE3
NCT00505934 COMPLETED
Epilepsy
UCB Pharma SA
 2008-05 PHASE2
NCT00419393 COMPLETED
Epilepsy
UCB Pharma
 2007-12 PHASE3
NCT00393614 UNKNOWN
Subclinical Sleep-Activated Epileptiform Activity; CSWS
Oslo University Hospital
 2007-05 PHASE4
NCT00535392 COMPLETED
Epilepsy
UCB Pharma
 2007-09 PHASE2
NCT00566046 TERMINATED
Epilepsy, Post-Traumatic
Rennes University Hospital
 2007-11 PHASE3
NCT01168687 COMPLETED
Alcohol Abuse; Drug Abuse
University of California, San Francisco
 2008-11
NCT00985348 COMPLETED
Healthy
UCB Pharma
 2009-09 PHASE1
NCT00618436 COMPLETED
Traumatic Brain Injury; Subarachnoid Hemorrhage
University of Cincinnati
 2007-08 PHASE4
NCT00571155 COMPLETED
Primary Brain Tumor; Epilepsy
University Hospital Tuebingen
 2007-12 PHASE4
NCT00758277 COMPLETED
Alcohol Dependence; Alcoholic Relapse
Charite University, Berlin, Germany
 2007-05 PHASE3
NCT00603135 WITHDRAWN
Status Epilepticus, Non-Convulsive
University Hospital, Basel, Switzerland
 2008-01 PHASE2
NCT00542802 UNKNOWN
Epileptic Seizures; Stroke
Scienze Neurologiche Ospedaliere
 2007-09 PHASE3
NCT00855738 COMPLETED
Focal Epilepsy
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2007-05 PHASE4
NCT00307450 COMPLETED
Parkinson's Disease
Technische Universität Dresden
 2006-03 PHASE4
NCT00279617 COMPLETED
Panic Disorder
Lindner Center of HOPE
 2006-01 PHASE3
NCT00926302 COMPLETED
Healthy
Tri-Service General Hospital (TSGH)
 2008-01
NCT00423527 COMPLETED
Multiple Sclerosis
Odense University Hospital
 2007-01 PHASE4
NCT00736931 COMPLETED
Epilepsy
UCB Pharma
 2008-07 PHASE1
NCT00566150 COMPLETED
Bipolar Depression
Yale University
 2005-10
NCT00286260 COMPLETED
Painful Polyneuropathy
Odense University Hospital
 2006-01 PHASE4
NCT00370838 COMPLETED
Tic Disorders; Tourette Syndrome
Harvey S. Singer
 2007-02 PHASE4
NCT00242606 COMPLETED
Epilepsy
Philipps University Marburg
 2005-03 PHASE3
NCT01463033 COMPLETED
Epilepsy; Post-traumatic Epilepsy
Pavel Klein
 2005-04 PHASE2
NCT00577005 COMPLETED
Cocaine Dependence; Opioid Dependency
Yale University
 2007-07 PHASE2
NCT00584025 WITHDRAWN
Parkinson's Disease
University of South Florida
 2007-12 PHASE4
NCT00152516 COMPLETED
Epilepsy, Partial
UCB Pharma
 2004-10 PHASE3
NCT00291655 COMPLETED
Epilepsy
UCB Pharma
 2006-06 PHASE3
NCT00376766 TERMINATED
Epilepsy; Drug Resistant
University Hospital, Grenoble
 2007-02 PHASE3
NCT01318408 COMPLETED
Epilepsy
Drexel University College of Medicine
 2006-11 PHASE4
NCT00620165 COMPLETED
Essential Tremor
Southern California Institute for Research and Education
 2005-01 PHASE1; PHASE2
NCT00252954 COMPLETED
Injuries, Spinal Cord; Pain
Danish Pain Research Center
 2005-11 PHASE4
NCT00627133 WITHDRAWN
Seizure, Alcohol Related
Medical University of South Carolina
 2008-02 PHASE2
NCT00265109 COMPLETED
Body Dysmorphic Disorder
Butler Hospital
 2004-12 PHASE4
NCT00141115 COMPLETED
Alcoholism; Generalized Anxiety Disorder; Panic Disorder; Social Phobia; Anxiety Disorders
New York State Psychiatric Institute
 2004-03 PHASE2
NCT00324454 COMPLETED
Motor Neuron Disease; Amyotrophic Lateral Sclerosis; Primary Lateral Sclerosis; Progressive Muscular Atrophy
Duke University
 2006-05 PHASE2
NCT00361010 COMPLETED
Epilepsy; Childhood Absence Epilepsy; Seizures
The Cleveland Clinic
 2006-12
NCT00299611 TERMINATED
Obsessive-Compulsive Disorder
Duke University
 2005-11 PHASE2; PHASE3
NCT00280696 COMPLETED
Epilepsies, Partial
UCB Japan Co. Ltd.
 2005-11 PHASE3
NCT00221988 COMPLETED
Epilepsy
University Hospitals Cleveland Medical Center
 2004-03
NCT00175903 COMPLETED
Epilepsy
UCB Pharma
 2005-02 PHASE3
NCT00760318 TERMINATED
Cervical Dystonia
University of South Florida
 2005-11 PHASE2
NCT00413296 COMPLETED
Post-Traumatic Stress Disorder
Duke University
 2005-11 PHASE2; PHASE3
NCT00593125 COMPLETED
Cocaine Dependence; Opioid Dependence
Yale University
 2007-01 PHASE2
NCT00146471 COMPLETED
Alcohol Withdrawal Syndrome
Charite University, Berlin, Germany
 2006-01 PHASE3
NCT00150748 COMPLETED
Generalized Epilepsy
UCB Pharma SA
 2001-11 PHASE3
NCT00415376 WITHDRAWN
Brain and Central Nervous System Tumors; Seizure; Unspecified Adult Solid Tumor, Protocol Specific
Northwestern University
 2007-02
NCT00826722 COMPLETED
Seizures
Roxane Laboratories
 2007-06
NCT00827320 COMPLETED
Seizures
Roxane Laboratories
 2007-06
NCT00150813 COMPLETED
Epilepsy, Tonic-clonic
UCB Pharma SA
 2005-08-10 PHASE3
NCT00105040 COMPLETED
Epilepsy, Partial
UCB Pharma
 2004-09 PHASE2
NCT00160615 COMPLETED
Epilepsy, Partial
UCB Japan Co. Ltd.
 2001-09-12 PHASE3
NCT00859430 COMPLETED
Healthy
Teva Pharmaceuticals USA
 2007-01 PHASE1
NCT00325182 COMPLETED
Alcoholism
Boston University
 2006-01 PHASE4
NCT00859521 COMPLETED
Healthy
Teva Pharmaceuticals USA
 2007-01 PHASE1
NCT00175890 COMPLETED
Epilepsy, Partial
UCB Pharma
 2004-10 PHASE3
NCT00160654 COMPLETED
Epilepsy, Partial
UCB Pharma
 2003-11-24 PHASE4
NCT00152503 COMPLETED
Epilepsy, Partial
UCB Pharma SA
 2005-08-31 PHASE2
NCT00291213 COMPLETED
Tardive Dyskinesia
Yale University
 PHASE3
NCT00150709 COMPLETED
Epilepsy, Partial
UCB Pharma
 1998-01-26 PHASE3
NCT00175955 COMPLETED
Dyskinesia, Medication-induced
UCB Pharma
 2005-05 PHASE2
NCT00849485 COMPLETED
Healthy
Teva Pharmaceuticals USA
 2005-11 PHASE1
NCT00849862 COMPLETED
Healthy
Teva Pharmaceuticals USA
 2005-10 PHASE1
NCT00150787 COMPLETED
Epilepsy, Tonic-clonic
UCB Pharma
 2003-07 PHASE3
NCT00223223 COMPLETED
Memory Loss Associated With Corticosteroid Use; Manic State Associated With Corticosteroid Use
University of Texas Southwestern Medical Center
 2005-02 PHASE4
NCT00826787 COMPLETED
Seizures
Roxane Laboratories
 2005-08
NCT00826865 COMPLETED
Seizures
Roxane Laboratories
 2005-08
NCT00160511 COMPLETED
Neuralgia, Postherpetic
UCB Pharma
 2004-04 PHASE2
NCT00150735 COMPLETED
Generalized Epilepsy
UCB Pharma
 2002-06 PHASE3
NCT00160550 COMPLETED
Generalized Convulsive Epilepsy
UCB Pharma
 2001-09 PHASE3
NCT00152373 COMPLETED
Epilepsy, Partial
UCB Pharma
 2004-07 PHASE3
NCT00254657 COMPLETED
Fibromyalgia
University of California, San Francisco
 2004-03
NCT00203216 COMPLETED
Migraine
Thomas Jefferson University
 2002-09
NCT00150774 COMPLETED
Generalized Convulsive Epilepsy
UCB Pharma
 2001-11 PHASE3
NCT00160576 COMPLETED
Idiopathic Parkinson Disease
UCB Pharma
 2003-07 PHASE2
NCT00245713 COMPLETED
Epilepsy, Partial
UCB Pharma
 2003-03 PHASE4
NCT00160628 COMPLETED
Epilepsy, Partial
UCB Pharma
 2004-03 PHASE3
NCT00610454 COMPLETED
Epilepsy
UCB Pharma
 2004-06 PHASE2
NCT00631150 COMPLETED
Epilepsy
UCB Pharma
 2003-03 PHASE4
NCT00630357 COMPLETED
Epilepsy
UCB Pharma
 2003-03 PHASE4
NCT00612859 COMPLETED
Anxiety Disorders
UCB Pharma
 2003-09 PHASE2
NCT00946751 COMPLETED
Seizure
Sandoz
 2004-03 PHASE1
NCT00630968 COMPLETED
Epilepsy
UCB Pharma
 2000-08 PHASE4
NCT00630630 COMPLETED
Epilepsy
UCB Pharma
 2002-11 PHASE4
NCT01132352 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2003-09 PHASE1
NCT01131897 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2003-09 PHASE1
NCT00600509 COMPLETED
Epilepsy
UCB Pharma
 2001-01 PHASE2
NCT00643500 COMPLETED
Epilepsy, Partial
UCB Pharma
 2002-01 PHASE4
NCT00545012 COMPLETED
Absence Seizures
UCB Pharma
 2000-05 PHASE2
NCT00544050 COMPLETED
Epilepsy
UCB Pharma
 2002-09 PHASE2
NCT00615615 COMPLETED
Epilepsy
UCB Pharma
 1999-09 PHASE3
NCT00181116 COMPLETED
Epilepsy
Johns Hopkins University
 2005-03 PHASE4
NCT00015769 COMPLETED
Bipolar Disorder
National Institute of Mental Health (NIMH)
 2001-04 PHASE2
NCT00156689 COMPLETED
Chronic Idiopathic Axonal Polyneuropathy
Vanderbilt University
 2005-08 PHASE2
NCT00076674 COMPLETED
Dyskinesias; Parkinson Disease
National Institute of Neurological Disorders and Stroke (NINDS)
 2004-01 PHASE2
NCT00518570 COMPLETED
Premenstrual Dysphoric Disorder
Berkshire Health Systems
 2003-11
NCT00262262 COMPLETED
Postoperative Pain
Odense University Hospital
 2004-03
NCT00291733 UNKNOWN
Levodopa Induced Dyskinesia
1st Hospital of Social Security Services
 2006-05 PHASE2
NCT00362141 UNKNOWN
Status Epilepticus
Medical Center Haaglanden
 2006-10 PHASE2
NCT00471744 TERMINATED
Epilepsy, Rolandic
Ludwig-Maximilians - University of Munich
 2006-06 PHASE3
NCT00247364 COMPLETED
Restless Legs Syndrome
Sleep Health Centers
 2003-11 PHASE2
NCT00208520 UNKNOWN
Adults With Tonic Clonic Seizures and/or Partial Seizures
Dutch Epilepsy Clinics Foundation
 2003-07

(data from https://clinicaltrials.gov, updated on 2025-10-24)

Check the Levetiracetam (UCB-L059) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Levetiracetam selectively binds to presynaptic synaptic vesicle protein 2A (SV2A) and modulates presynaptic P/Q-type voltage-dependent calcium channels, thereby inhibiting vesicular exocytosis and neurotransmitter release. This suppression of hypersynchronous neuronal discharge dampens pathological synaptic transmission, providing therapeutic efficacy in controlling seizure activity across diverse epileptic conditions such as status epilepticus and partial-onset seizures.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.